A Novel Method for Preparing Uniform Micro-Sized Dry Powder Formulations, Including Aggregation-Controlled VHH
Antibodies,
Год журнала:
2025,
Номер
14(2), С. 29 - 29
Опубликована: Март 31, 2025
Background:
The
preparation
of
antibodies
in
powder
form
without
changing
their
physicochemical
properties
may
enable
use
new
drug
delivery
system
therapies
or
non-refrigerated
storage.
variable
domain
heavy-chain
(VHHs)
is
more
suited
for
this
purpose
than
that
conventional
because
VHHs’
high
thermal
stability
and
ability
to
refold.
Methods:
In
report,
the
fine
droplet
drying
(FDD)
process
was
selected
as
powderization
technique
its
favorable
features,
such
mild
conditions
generation
uniform
particle
sizes.
aggregation,
binding,
particle,
vitro
inhalation
prepared
VHH
powders
(VHHps)
were
evaluated.
Results:
amount
aggregated
VHHs
present
VHHps
depended
on
flow
temperature
during
FDD
process,
with
higher
temperatures
yielding
a
aggregation
ratio.
contrast,
no
significant
difference
binding
activity
observed
between
each
VHHp
native
VHHs.
However,
degraded
inactivated
function,
ultimately,
only
about
30%
original
functional,
whereas
remaining
not
showed
little
loss
functionality,
even
after
storage
at
room
two
years.
Analysis
samples
revealed
particles
uniformly
spherical
single-micron
size.
property
test.
Conclusions:
These
findings
suggest
affords
various
formulations,
including
pharmaceutical
formulations.
Язык: Английский
Formulation and clinical translation of inhalable nanomedicines for the treatment and prevention of pulmonary infectious diseases
Drug Delivery and Translational Research,
Год журнала:
2025,
Номер
unknown
Опубликована: Апрель 29, 2025
Abstract
Pulmonary
infections
caused
by
bacteria,
viruses
and
fungi
are
a
significant
global
health
issue.
Inhalation
therapies
gaining
interest
as
an
effective
approach
to
directly
target
infected
lung
sites
nanoparticle-based
pulmonary
delivery
systems
increasingly
investigated
for
this
purpose.
In
review,
we
provide
overview
of
common
infectious
diseases
review
recent
work
on
the
application
inhalable
formulations
diseases,
formulation
strategies,
current
research
delivering
nanomedicines.
We
also
evaluate
clinical
development
status,
market
landscape,
discuss
challenges
that
impede
translation
propose
solutions
overcome
these
obstacles,
highlighting
promising
opportunities
future
advancements
in
field.
Despite
made
products
reaching
market,
notable
gap
persists
translational
research,
with
achieving
product
profile,
availability
appropriate
vivo
disease
models,
scale-up,
related
questions,
likely
hindering
clinic.
Graphical
Язык: Английский
Unveiling the role of nanoparticle-based therapeutic strategies for pulmonary drug delivery
Journal of Drug Delivery Science and Technology,
Год журнала:
2024,
Номер
unknown, С. 106558 - 106558
Опубликована: Дек. 1, 2024
Язык: Английский
Nanoparticle-Mediated Delivery of Deferasirox: A Promising Strategy Against Invasive Aspergillosis
Sydney Peppe,
M. Javad Farrokhi,
Evan A. Waite
и другие.
Bioengineering,
Год журнала:
2024,
Номер
11(11), С. 1115 - 1115
Опубликована: Ноя. 5, 2024
Invasive
aspergillosis
(IA)
is
a
deadly
fungal
lung
infection.
Antifungal
resistance
and
treatment
side
effects
are
major
concerns.
Iron
chelators
vital
for
IA
management,
but
systemic
use
can
cause
effects.
We
developed
nanoparticles
(NPs)
to
selectively
deliver
the
iron
chelator
deferasirox
(DFX)
treatment.
Язык: Английский